Althea & Profectus Biosciences Sign Manufacturing Agreement
News Mar 01, 2013
Althea Technologies, Inc. and Profectus BioSciences Inc, have announced the signing of a manufacturing supply agreement for plasmid DNA production.
Under the agreement, Althea will provide gram-scale quantities of cGMP (current Good Manufacturing Practice) manufactured plasmid DNA expressing IL-12 to assist Profectus Biosciences’ ongoing DNA vaccine development efforts, which are supported by a contract from the National Institutes of Health.
IL-12 helps prompt an immune response once the DNA enters a cell, which is part of Profectus Bioscience’s technology platform designed to overcome the poor delivery and immunogenicity of many DNA vaccines.
“Profectus is very pleased to establish this partnership with Althea for the production of the clinical grade plasmids for our DNA vaccine programs,” said John Eldridge, Chief Scientific Officer of Profectus BioSciences. “Althea provides an unmatched combination of state-of-the-art facilities and expertise in this area and we anticipate a long and productive association.”
“We are delighted to be awarded this contract, this project has tremendous potential for treating some of the world’s most devastating and challenging diseases” stated Rick Hancock, President and CEO of Althea Technologies.
Hancock continued, “By establishing this partnership, Althea will be able to leverage our plasmid manufacturing expertise to help advance this DNA vaccines program through the clinic and to the patients who need it.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE